Jasper Therapeutics Q2 net loss $26.7M; cuts workforce 50%, probes BEACON lot issue

Jasper Therapeutics, Inc.

2025-Q2 EPS reported -$3.16

Net loss of $26.7M ($1.74 per share); cash and equivalents $39.5M as of June 30, 2025.
BEACON study: 89% complete response in 240/360 mg single-dose cohorts; investigation into 240mg Q8W/240/180mg Q8W cohorts due to potential product lot variability.
Workforce reduction of ~50% to focus on urticaria; CMO Dr. Edwin Tucker stepped down, succeeded by Dr. Daniel Adelman as interim.
Halted non-mast cell programs (SCID, asthma ETESIAN study) to concentrate on briquilimab in CSU and CIndU.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.